



AMENDMENTS TO THE CLAIMS

Claims 1-30 (cancelled)

Claim 31 (currently amended): A method for affecting promoting the survival or function of dopaminergic neurons comprising administering a polynucleotide consisting of a polynucleotide sequence encoding a truncated glial cell line-derived neurotrophic factor (GDNF) protein product consisting of an amino acid sequence

X-[Cys⁴¹-Cys¹³³]-Y

wherein

[Cys⁴¹-Cys¹³³] consists of Cys⁴¹ through Cys¹³³ of SEQ ID NO 2;

Y represents the carboxy terminal group of Cys¹³³, a carboxy-terminus amino acid residue of Ile¹³⁴, or a substituted amino acid residue, and

X represents a methionylated or nonmethionylated amine group of Cys⁴¹ or amino-terminus amino acid residue(s) selected from the group:

RECEIVED

G

RG

NRG

AUG 04 2003

TECH CENTER 1600/2900

KNRG (SEQ ID NO:3)

GKNRG (SEQ ID NO:4)

RGKNRG (SEQ ID NO:5)

QRGKNRG (SEQ ID NO:6)

GQRGKNRG (SEQ ID NO:7)

RGQRGKNRG (SEQ ID NO:8)

RRGQRGKNRG (SEQ ID NO:9)

G RRGQRGKNRG (SEQ ID NO:10)

KG RRGQRGKNRG (SEQ ID NO:11)

GKG RRGQRGKNRG (SEQ ID NO:12)

RGKG RRGQRGKNRG (SEQ ID NO:13)

SRGKG RRGQRGKNRG (SEQ ID NO:14)

NSRGKG RRGQRGKNRG (SEQ ID NO:15)

ENSRGKG RRGQRGKNRG (SEQ ID NO:16)

PENSRGKG RRGQRGKNRG (SEQ ID NO:17)

SPENSRGKG RRGQRGKNRG (SEQ ID NO:51)

NPENSRGKG RRGQRGKNRG (SEQ ID NO:18)

ANPENSRGKG RRGQRGKNRG (SEQ ID NO:19)

A ANPENSRGKG RRGQRGKNRG (SEQ ID NO:20)

AA ANPENSRGKG RRGQRGKNRG (SEQ ID NO:21)

AAA	ANPENSRGKG	RRGQRGKNRG	(SEQ ID NO:22)
QAAA	ANPENSRGKG	RRGQRGKNRG	(SEQ ID NO:23)
RQAAA	ANPENSRGKG	RRGQRGKNRG	(SEQ ID NO:24)
NRQAAA	ANPENSRGKG	RRGQRGKNRG	(SEQ ID NO:25)
RNRQAAA	ANPENSRGKG	RRGQRGKNRG	(SEQ ID NO:26)
ERNRQAAA	ANPENSRGKG	RRGQRGKNRG	(SEQ ID NO:27)
RERNRQAAA	ANPENSRGKG	RRGQRGKNRG	(SEQ ID NO:28)
RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG	(SEQ ID NO:29)
P	RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG (SEQ ID NO:30)
LP	RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG (SEQ ID NO:31)
VLP	RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG (SEQ ID NO:32)
AVLP	RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG (SEQ ID NO:33)
MAVLP	RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG (SEQ ID NO:34)
QMAVLP	RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG (SEQ ID NO:35)
KQMAVLP	RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG (SEQ ID NO:36)
DKQMAVLP	RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG (SEQ ID NO:37) and
PDKQMAVLP	RRERNRQAAA	ANPENSRGKG	RRGQRGKNRG (SEQ ID NO:38)

or a substitution or deletion variant of X, wherein said variant is in excess of 70% identical to an amino acid sequence of X as set forth above when four gaps in a length of 100 amino acids may be introduced to assist in that alignment, to provide *in vivo* production of said truncated GDNF protein.

B1
cont
Claims 32-44 (cancelled)

Claim 45 (currently amended): A method according to Claim 31 or 32, wherein X is selected from the group consisting of SEQ ID NO: 3, 7, 8, 14, 17, and 18 and 24.

Claim 46 (previously presented): A method according to Claim 31 or 32, wherein X is G, RG or NRG.

Claim 47 (previously presented): A method according to Claim 31 or 32, wherein said GDNF protein product has the amino acid sequence of SEQ ID NO:42.

B
Claim 48 (previously presented): A method according to Claim 31 or 32, wherein said GDNF protein product has the amino acid sequence of SEQ ID NO:44.

Claim 49 (previously presented): A method according to Claim 31 or 32, wherein said GDNF protein product has the amino acid sequence of SEQ ID NO:46.